Suppr超能文献

7至22个月大儿童白内障手术及一期人工晶状体植入的长期效果

Long-term results of pediatric cataract surgery and primary intraocular lens implantation from 7 to 22 months of life.

作者信息

Struck Michael C

机构信息

Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison.

出版信息

JAMA Ophthalmol. 2015 Oct;133(10):1180-3. doi: 10.1001/jamaophthalmol.2015.2062.

Abstract

IMPORTANCE

Pediatric primary posterior intraocular lens (IOL) implantation in children older than 24 months has become the standard of care. Results of the Infantile Aphakia Treatment Study have concluded that primary IOL implantation before age 7 months has no advantages over aphakia. The current evidence does not address our understanding of the risks and benefits of primary IOL implantation for children aged 7 to 24 months.

OBSERVATIONS

Final optotype acuity, adverse events, refractive growth, strabismus, binocular function, and need for additional surgery were retrospectively reviewed for 14 eyes of 10 patients from November 2001 to June 2012. The records were reviewed for children aged 6 to 24 months; included patients were aged 7 to 22 months. The mean (SD) visual acuity was 0.29 (0.30) logMAR (Snellen equivalent 20/40). The mean follow-up was 5 years. The rate of adverse events was 3 in 14 eyes (21%). Adverse events included lens reproliferation (2 eyes) and lens dislocation (1 eye). The rate of strabismus correction was 4 in 10 patients (40%). The mean (SD) rate of refractive growth at 3 times the age at surgery was -5.80 (3.09) diopters.

CONCLUSIONS AND RELEVANCE

The data suggest that primary IOL implantation in this age group has a lower rate of adverse events than reported in the Infantile Aphakia Treatment Study. Additionally, favorable visual outcome was found, similar to that in children undergoing primary IOL implantation when older than 2 years. Primary IOL implantation should be considered in children who require cataract surgery after age 7 months.

摘要

重要性

在24个月以上儿童中进行小儿原发性后房型人工晶状体(IOL)植入已成为标准治疗方法。婴幼儿无晶状体治疗研究的结果表明,7个月前进行原发性IOL植入并不比无晶状体状态有优势。目前的证据并未解决我们对7至24个月儿童原发性IOL植入的风险和益处的理解问题。

观察结果

对2001年11月至2012年6月期间10例患者的14只眼进行回顾性分析,评估最终视标视力、不良事件、屈光发育、斜视、双眼功能以及额外手术需求。对6至24个月的儿童记录进行了审查;纳入患者年龄为7至22个月。平均(标准差)视力为0.29(0.30)logMAR(Snellen等效值20/40)。平均随访时间为5年。不良事件发生率为14只眼中有3只(21%)。不良事件包括晶状体再增殖(2只眼)和晶状体脱位(1只眼)。10例患者中有4例(40%)进行了斜视矫正。手术年龄3倍时的平均(标准差)屈光发育率为-5.80(3.09)屈光度。

结论及相关性

数据表明,该年龄组原发性IOL植入的不良事件发生率低于婴幼儿无晶状体治疗研究报告的发生率。此外,发现视觉预后良好,与2岁以上接受原发性IOL植入的儿童相似。对于7个月龄后需要进行白内障手术的儿童,应考虑原发性IOL植入。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验